C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 1 filers reported holding C4 THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,801 | -11.6% | 12,259 | +30.7% | 0.00% | 0.0% |
| Q2 2023 | $25,801 | +214908.3% | 9,382 | +144.6% | 0.00% | – |
| Q1 2023 | $12 | +33.3% | 3,836 | +156.2% | 0.00% | – |
| Q4 2022 | $9 | -100.0% | 1,497 | -85.2% | 0.00% | -100.0% |
| Q3 2022 | $89,000 | +323.8% | 10,100 | +256.6% | 0.00% | – |
| Q2 2022 | $21,000 | -92.2% | 2,832 | -74.3% | 0.00% | -100.0% |
| Q1 2022 | $268,000 | +72.9% | 11,036 | +128.6% | 0.00% | 0.0% |
| Q4 2021 | $155,000 | +23.0% | 4,827 | +70.9% | 0.00% | 0.0% |
| Q3 2021 | $126,000 | +186.4% | 2,824 | +146.9% | 0.00% | +200.0% |
| Q2 2021 | $44,000 | -42.1% | 1,144 | -44.9% | 0.00% | 0.0% |
| Q1 2021 | $76,000 | +744.4% | 2,076 | +625.9% | 0.00% | – |
| Q4 2020 | $9,000 | – | 286 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $17,795,000 | 7.09% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $60,745,000 | 3.44% |
| Soleus Capital Management, L.P. | 464,068 | $17,166,000 | 3.09% |
| Cormorant Asset Management, LP | 2,490,065 | $92,107,000 | 2.05% |
| P.A.W. CAPITAL CORP | 50,000 | $1,850,000 | 1.63% |
| Perceptive Advisors | 3,158,566 | $116,835,000 | 1.48% |
| SPHERA FUNDS MANAGEMENT LTD. | 497,136 | $18,389,000 | 1.41% |
| Mizuho Securities Co. Ltd. | 169,392 | $6,266,000 | 1.30% |
| RTW INVESTMENTS, LP | 2,149,228 | $79,437,000 | 1.24% |
| Darwin Global Management, Ltd. | 140,034 | $5,180,000 | 1.01% |